Systemic Recombinant α–2Interferon Therapy in Relapsing Multiple Sclerosis

Archives of Neurology

Volumn 43, Issue 12, 1986, Pages 1238-1246

  Camenga, David L ^a   Johnson, Kenneth P ^a   Alter, Milton ^b   Engelhardt, Charles D ^a   Fishman, Paul S ^a   Greenstein, Jeffrey I ^b   Haley, Andrea Sue ^a   Hirsch, Robert L ^a   Kleiner, Judith E ^b   Kofie, Vincent Y ^c   Koski, Carol Lee ^a   Margulies, Sheldon L ^a   Panitch, Hillel S ^a   Valero, Reuben ^d  

^a Maryland Center for Multiple Sclerosis Research and Treatment ^*  (United States)

^b UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; CORTICOSTEROID; PLACEBO; RECOMBINANT ALPHA2 INTERFERON;

ADVERSE DRUG REACTION; ALOPECIA; CENTRAL NERVOUS SYSTEM; CHILL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG THERAPY; DRUG TOLERANCE; FEVER; HUMAN; INFLUENZA; INTOXICATION; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NERVOUS SYSTEM; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; THERAPY;

ADULT; CLINICAL TRIALS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE I; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; RANDOM ALLOCATION; RECOMBINANT PROTEINS; SELF ADMINISTRATION;

EID: 0023039442     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.1986.00520120023011     Document Type: Article

References (27)

1. Charcot JM: Lectures on the Diseases of the Nervous System: Delivered at La Salpetriere, Sigerson G (trans). London, New Sydenham Society, 1877-1889.
2. Aronson SM, Bauer HJ, Brown JR, et al: Therapeutic Claims in Multiple Sclerosis. New York, National Multiple Sclerosis Society, 1982.
3. Scheinberg L, Raine CS (eds): Multiple sclerosis: Experimental and clinical aspects. Ann NY Acad Sci 1984;436:1-518.
4. Matthews WB: Treatment, in Matthews WB, Acheson ED, Batchelor JR (eds): McAlpine's Multiple Sclerosis. New York, Churchill Livingstone Inc, 1985, chap 10, pp 233-278.
5. Isaacs A, Lindeman J: Virus interference: I. The interferon. Proc R Soc Lond 1957;147:258-267.
6. Gresser I, Burke D, Cantell K, et al: Interferon 6 1985. Orlando, Fla, Academic Press, 1985.
7. Cantell K, Hirvonen S: Large-scale production of human leukocyte interferon containing 108 units per milliliter. J Gen Virol 1978;39:541-543.
8. Fantes KH, Finter NB: Large-scale preparation of interferon-αfor clinical use, in Zoon KC, Noguchi PD, Liu TY (eds): Interferon: Research, Clinical Application, and Regulatory Consideration. New York, Elsevier Science Publishing Co Inc, 1984.
9. Neighbor PA, Bloom BR: Absence of virusinduced lymphocyte suppression and interferon production in multiple sclerosis. Proc Natl Acad Sci USA 1979;76:476-480.
10. Neighbor PA, Miller AE, Bloom BR: Interferon responses of leukocytes in multiple sclerosis. Neurology 1981;31:561-566.
11. Neighbor PA, Grayzel AI, Miller AE: Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro: Study of patients with multiple sclerosis, systemic lupus erythematosus, or rheumatoid arthritis. Clin Exp Immunol 1982;49:11-21.
12. Johnson KP: Systemic interferon therapy for multiple sclerosis: Design of a trial. Arch Neurol 1983;40:681-682.
13. Panitch HS, Knobler RL, Francis GS, et al: A trial of natural a-interferon in the treatment of multiple sclerosis: II. Clinical results. Neurology 1984;34(suppl 1):111.
14. Kamin-Lewis RM, Panitch HS, Merigan TC, et al: Decreased interferon synthesis and responsiveness to interferon by leukocytes from multiple sclerosis patients given natural α-interferon. J Interferon Res 1984;4:423-432.
15. Jacobs L, O'Malley J, Freeman A, et al: Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981;214:1026-1028.
16. Ruutiainen J, Panelius M: Toxic effects of interferon administered intrathecally. Br Med J 1983;286:940.
17. Billiau A, Heremans H, Ververken D, et al: Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice. Arch Virol 1981;68:19-25.
18. Habif DV, Lipton R, Cantell K: Interferon crosses blood-cerebrospinal fluid barrier in monkeys. Proc Soc Exp Biol Med 1975;149:287-289.
19. Poser CM, Paty DW, Scheinberg L, et al: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227-231.
20. International Federation of Multiple Sclerosis Societies: Minimal Record of Disability, 1983. Acta Neurol Scand 1984;70(suppl 101):169-190.
21. Lundberg GD, Iverson C, Radulescu G: Now read this: The SI units are here, editorial. Arch Neurol 1986;43:547-557.
22. Knobler RL, Panitch HS, Braheny SL, et al: Systemic α-interferontherapy of multiple sclerosis. Neurology 1984;34:1273-1279.
23. Mickey MR, Ellison GW, Myers LW: An illness severity score for multiple sclerosis. Neurology 1984;34:1343-1347.
24. Hirsch RL, Johnson KP: Natural killer cell activity in multiple sclerosis patients treated with recombinant interferon α-2.Clin Immunol Immunopathol 1985;37:236-244.
25. Hirsch RL, Johnson KP: The effect of recombinant alpha-2 interferon on defective natural killer cell activity in multiple sclerosis. Neurology 1985;35:597-599.
26. Hirsch RL, Johnson KP: Placebo-induced enhancement of natural killer cell activity in a double-blind trial of recombinant α-2interferon in multiple sclerosis patients, in Spector NH (ed): Neuroimmunomodulation: Proceedings of the First International Workshop on Neuroimmuno modulation. Bethesda, Md, International Working Group on Neuroimmunomodulation, 1985.
27. Sibley WA, Bamford CR, Clark K: Clinical viral infections and multiple sclerosis. Lancet 1985;1:1313-1315.